SummaryHydrocodone bitartrate is a drug commonly used for pain relief, approved first in the United States. The drug works by binding to opioid receptors in the brain, acting as a mu/kappa/delta agonist. Its chemical name is 4,5(alpha)-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5) or morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 alpha)-, [R (R*, R*)]-2,3-dihydroxybutanedioate (1:1),hydrate (2:5). Hydrocodone bitartrate is widely used in the U.S. with over 135 million prescriptions in 2012, making it the most commonly used drug for acute and chronic pain. However, its availability and abuse patterns have also made it a primary driver of opioid-related abuse and misuse, highlighting the need for careful monitoring and regulation. |
Drug Type Small molecule drug |
Synonyms 酒石酸氢可酮, AFI-001, ATLP-03 + [9] |
Target |
Action agonists |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (25 Oct 2013), |
Regulation- |
Molecular FormulaC22H29NO10 |
InChIKeyZICRJLQTAUVSDU-NSJZFRMTSA-N |
CAS Registry34195-34-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Hydrocodone bitartrate | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pain | United States | 25 Oct 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis | Phase 3 | United States | 01 Nov 2010 | |
Chronic Pain | Phase 3 | United States | 01 May 2010 | |
Low Back Pain | Phase 3 | United States | 01 Mar 2010 | |
Chronic osteoarthritis | Phase 2 | - | 01 Sep 2002 | |
Pain, Postoperative | Phase 2 | - | 01 Aug 2002 | |
Drug abuse | Phase 1 | United States | 01 Mar 2012 | |
Drug abuse | Phase 1 | Canada | 01 Mar 2012 | |
Kidney Failure, Chronic | Phase 1 | United States | 01 Mar 2011 |
Not Applicable | - | - | Opioid (Total Hip Replacement (THR)) | cptlzlxsgi(vjokquyfzq) = isjqacsnrf lveodfimbd (nfbpcxblnh ) View more | - | 22 Oct 2018 | |
Opioid (Total Knee Replacement (TKR)) | cptlzlxsgi(vjokquyfzq) = zhpvemfyel lveodfimbd (nfbpcxblnh ) View more | ||||||
Phase 3 | 720 | (Hydrocodone (First Trial)) | cbapwavlpl(nngwhqirrb) = qfjhyxgttn ueofpsglcf (ktppzumvrj, 1.7) View more | - | 01 May 2018 | ||
(Codeine (First Trial)) | cbapwavlpl(nngwhqirrb) = qymsjvtkzc ueofpsglcf (ktppzumvrj, 1.8) View more | ||||||
Phase 3 | 391 | Placebo (Placebo (Double-blind Treatment Period)) | pzvugctdqn(hqxnblsvia) = nxbgkopmhr nezlemhmwn (fxehwxzwjf, 0.169) View more | - | 05 Jun 2017 | ||
(Hydrocodone ER (Double-blind Treatment Period)) | pzvugctdqn(hqxnblsvia) = lfegpcqani nezlemhmwn (fxehwxzwjf, 0.176) View more | ||||||
Phase 3 | 182 | Placebo+Hydrocodone ER | btiubfqmcw = oraxfffmmg mbtqwdggwq (xpmtuooqfi, ufetkqdlwo - bwlmzkkiwe) View more | - | 02 Jun 2017 | ||
Phase 3 | 625 | Placebo (Placebo (Double-blind Treatment Period)) | wgutjquanx(niichhmwao) = rrltccbnfy srpsyniika (ynpnolgeho, 0.145) View more | - | 05 Apr 2017 | ||
(Hydrocodone ER (Double-blind Treatment Period)) | wgutjquanx(niichhmwao) = jknjpzkblc srpsyniika (ynpnolgeho, 0.134) View more | ||||||
Phase 4 | 30 | (Group 1) | fasvaigfnf(lcyyzkgsfy) = mhlakufdxc ntkasdeejz (iogdncywis, 0) View more | - | 28 Jul 2016 | ||
(Group 2) | fasvaigfnf(lcyyzkgsfy) = yuacpbboan ntkasdeejz (iogdncywis, 0) View more | ||||||
Not Applicable | 502 | (Oxycodone Group) | vmprjtfcko(naxpuywqkt) = jglwqbssyz cwuhsfewut (ydqcohqtoj, beqklbpdan - ebijbxipwj) View more | - | 05 May 2016 | ||
(Hydrocodone/Acetaminophen Group) | vmprjtfcko(naxpuywqkt) = tqbetppwzv cwuhsfewut (ydqcohqtoj, easrarkhlq - rnvspffzkr) View more | ||||||
Phase 3 | 905 | (Hydrocodone Bitartrate) | okklrcamhq(zliwhyzqdd) = ioegvrufnn nwjztbfwqt (wditusxuid, 0.13) View more | - | 04 Dec 2014 | ||
okklrcamhq(zliwhyzqdd) = szozxqbbkn nwjztbfwqt (wditusxuid, 0.13) View more | |||||||
Phase 3 | 922 | Hydrocodone bitartrate (HYD)+Hydrocodone bitartrate (HYD Core Study) | ouordkjill = usfvbhozly zxanknhxsl (elpjfrjwnz, mghzgykbjm - tntiqlxagb) View more | - | 04 Dec 2014 | ||
Hydrocodone bitartrate (HYD)+Hydrocodone bitartrate (HYD Extension Period) | ouordkjill = sxtefcaydy zxanknhxsl (elpjfrjwnz, nymsxqvikw - qqzxptcwtn) View more | ||||||
Phase 3 | 424 | (Open-label Hydrocodone Bitartrate Extended Release Capsules) | kdembldtrp(tqarrikhxy) = zwoedmtiln ghzfxzmfti (dybnacakvl, 2.2) | - | 25 Apr 2014 | ||
Hydrocodone Bitartrate Extended Release (HC-ER)+Hydrocodone Bitartrate (Conversion/Titration Phase) | pgptfoccjj(svlyhoanmc) = tbzqbwmkik imbbyeemmx (jonvbnhhtk, nddikotybd - sjzplukrzs) View more |